Arkadios Wealth Advisors Raises Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Arkadios Wealth Advisors increased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 5.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 27,964 shares of the company’s stock after purchasing an additional 1,379 shares during the period. Arkadios Wealth Advisors’ holdings in Amphastar Pharmaceuticals were worth $1,038,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in AMPH. GAMMA Investing LLC boosted its stake in Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after purchasing an additional 273 shares during the period. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Amphastar Pharmaceuticals by 53.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after buying an additional 398 shares during the period. Asset Management One Co. Ltd. purchased a new position in shares of Amphastar Pharmaceuticals during the third quarter worth about $78,000. Mirae Asset Global Investments Co. Ltd. increased its position in Amphastar Pharmaceuticals by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after acquiring an additional 301 shares during the period. Finally, nVerses Capital LLC raised its stake in Amphastar Pharmaceuticals by 18.2% during the 3rd quarter. nVerses Capital LLC now owns 2,600 shares of the company’s stock valued at $126,000 after acquiring an additional 400 shares during the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $35.70 on Monday. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $34.60 and a 12-month high of $56.88. The company has a market cap of $1.72 billion, a price-to-earnings ratio of 11.90, a price-to-earnings-growth ratio of 1.12 and a beta of 0.82. The stock has a 50 day simple moving average of $41.15 and a 200-day simple moving average of $44.12.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 7,426 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $386,523.30. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at $4,898,061.15. This trade represents a 7.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Rong Zhou sold 7,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the sale, the executive vice president now owns 118,469 shares in the company, valued at approximately $5,262,392.98. The trade was a 5.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,533 shares of company stock valued at $1,987,482. 27.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Wells Fargo & Company began coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price on the stock. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $60.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.